Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 253-262

  Geoerger, Birgit ^a   Kieran, Mark W ^b   Grupp, Stephan ^c   Perek, Danuta ^d   Clancy, Jill ^e   Krygowski, Mizue ^f   Ananthakrishnan, Revathi ^e   Boni, Joseph P ^g   Berkenblit, Anna ^g   Spunt, Sheri L ^h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^e SYNEOS HEALTH   (United States)

^f PFIZER INC   (United States)

^g Pfizer Oncology   (United States)

^h UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adolescent; Child; Clinical trial; Glioma; mTOR; Neuroblastoma; Phase II; Rhabdomyosarcoma; Temsirolimus

Indexed keywords

TEMSIROLIMUS;

ADOLESCENT; ADULT; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; FEMALE; FEVER; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFANT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUROBLASTOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PONTINE GLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RHABDOMYOSARCOMA; SCHOOL CHILD; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEUROBLASTOMA; RHABDOMYOSARCOMA; SIROLIMUS;

EID: 84655175068     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.021     Document Type: Article

References (42)

1. P. Kaatsch Epidemiology of childhood cancer Cancer Treat Rev 36 2010 277 285
2. M.A. Smith, N.L. Seibel, and S.F. Altekruse Outcomes for children and adolescents with cancer: challenges for the twenty-first century J Clin Oncol 28 2010 2625 2634
3. J.A. Punyko, A.C. Mertens, and J.G. Gurney Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study Pediatr Blood Cancer 44 2005 643 653 (Pubitemid 40629215)
4. G.T. Armstrong, Q. Liu, and Y. Yasui Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study J Natl Cancer Inst 101 2009 946 958
5. G.T. Armstrong, Q. Liu, and Y. Yasui Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study J Clin Oncol 27 2009 2328 2338
6. J.M. Maris Recent advances in neuroblastoma N Engl J Med 362 2010 2202 2211
7. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 2004 335 348 (Pubitemid 38579480)
8. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22 (Pubitemid 47001784)
9. J.J. Gibbons, R.T. Abraham, and K. Yu Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth Semin Oncol 36 2009 S3 S17
10. R.T. Abraham, and J.J. Gibbons The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy Clin Cancer Res 13 2007 3109 3114 (Pubitemid 46944891)
11. D. Del Bufalo, L. Ciuffreda, and D. Trisciuoglio Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus Cancer Res 66 2006 5549 5554 (Pubitemid 43927103)
12. B. Geoerger, K. Kerr, and C.B. Tang Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Res 61 2001 1527 1532 (Pubitemid 34292583)
13. L. Dudkin, M.B. Dilling, and P.J. Cheshire Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 2001 1758 1764 (Pubitemid 32708646)
14. J.I. Johnsen, L. Segerstrom, and A. Orrego Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo Oncogene 27 2008 2910 2922 (Pubitemid 351620441)
15. X. Wan, N. Shen, A. Mendoza, C. Khanna, and L.J. Helman CCI-779 Inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1alpha/VEGF signaling Neoplasia 8 2006 394 401 (Pubitemid 43830746)
16. X. Wan, A. Mendoza, C. Khanna, and L.J. Helman Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma Cancer Res 65 2005 2406 2411 (Pubitemid 40490152)
17. A. Iwamaru, Y. Kondo, and E. Iwado Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells Oncogene 26 2007 1840 1851 (Pubitemid 46474638)
18. S.L. Spunt, S.A. Grupp, and T.A. Vik Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors J Clin Oncol 29 2011 2933 2940
19. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
20. G.M. Brodeur, J. Pritchard, and F. Berthold Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment J Clin Oncol 11 1993 1466 1477 (Pubitemid 23228250)
21. C.J. Punt, J. Boni, U. Bruntsch, M. Peters, and C. Thielert Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors Ann Oncol 14 2003 931 937 (Pubitemid 36827210)
22. J.P. Boni, B. Hug, C. Leister, and D. Sonichsen Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations Semin Oncol 36 2009 S18 S25
23. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
24. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
25. G. Hess, R. Herbrecht, and J. Romaguera Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829
26. J.L. Frazier, J. Lee, and U.W. Thomale Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies J Neurosurg Pediatr 3 2009 259 269
27. B. Geoerger, D. Hargrave, and F. Thomas Innovative therapies for children with cancer: pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors Neuro Oncol 13 2010 109 118
28. E. Galanis, J.C. Buckner, and M.J. Maurer Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 2005 5294 5304 (Pubitemid 46206983)
29. G.M. Brodeur Getting into the AKT J Natl Cancer Inst 102 2010 747 749
30. A.J. Pantuck, D.B. Seligson, and T. Klatte Prognostic relevance of the mTOR pathway in renal cell carcinoma Cancer 109 2007 2257 2267
31. B. Coiffier, and V. Ribrag Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies Leuk Lymphoma 50 2009 1916 1930
32. Liao S, Spunt SL, Shapiro M, Boni JP. Population pharmacokinetics of temsirolimus in pediatric patients with relapsed/refractory solid tumors. Presented at: the 35th Annual European Society for Medical Oncology Conference; Milan, Italy, October 8-12; 2010 [abstract].
33. B. Shor, W.G. Zhang, and L. Toral-Barza A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis Cancer Res 68 2008 2934 2943 (Pubitemid 351556294)
34. Temsirolimus and valproic acid in treating young patients with relapsed neuroblastoma, bone sarcoma, or soft tissue sarcoma [ NCT01204450 ]. Available at: < www.clinicaltrials.gov >; 2011 [accessed April 25, 2011].
35. Safety and efficacy study of Torisel and liposomal doxorubicin for patients with recurrent sarcoma [ NCT00949325 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 25, 2011].
36. Doxil, bevacizumab and temsirolimus trial [ NCT00761644 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 26, 2011].
37. Perifosine with temsirolimus for recurrent pediatric solid tumors [ NCT01049841, accessed April 26, 2011].
38. IMC-A12 in combination with temsirolimus (CCI-779) in patients with advanced cancers [ NCT00678769; NCT00678769 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 26, 2011].
39. A phase I Study of IMC-A12 in combination with temsirolimus in pediatric patients with recurrent or refractory solid tumors [ NCT01182883 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 26, 2011].
40. Cixutumumab and temsirolimus in treating young patients with solid tumors that have recurred or not responded to treatment [ NCT00880282 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 25, 2011].
41. Vinorelbine ditartrate and cyclophosphamide in combination with bevacizumab or temsirolimus in treating patients with recurrent or refractory rhabdomyosarcoma [ NCT01222715 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 26, 2011].
42. Temsirolimus, irinotecan hydrochloride, and temozolomide in treating young patients with relapsed or refractory solid tumors [ NCT01141244 ]. Available from: < www.clinicaltrials.gov >; 2011 [accessed April 26, 2011].